Eyenovia Q1 net loss $10.9M, up from $5.7M; advances MicroPine and clobetasol pipeline

HYPERION DEFI, INC.

2024-Q1 EPS reported -$0.23 revenue$4,993

Net loss Q1 2024 $10.9M ($0.23/shr) vs $5.7M ($0.15/shr) in Q1 2023; includes $2.5M charge for MicroPine license reacquisition.
R&D expenses $4.4M (+75.7% YoY), G&A $3.8M (+30.6% YoY); total operating expenses $10.3M (+88.1% YoY).
Cash and equivalents $8.0M at March 31, 2024; additional $2.2M raised in April 2024.
MicroPine Phase 3 CHAPERONE DMC review planned for early Q4 2024; clobetasol launch targeted for Q3 2024.
Mydcombi rollout: 50 new offices trained; reduced cash expenses by ~$0.8M per quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HYPERION DEFI, INC. reported the first quarter ended March 31, 2024 results: net income net loss was approximately $10.9 million, EPS $0.23 per share.

Period: the first quarter ended March 31, 2024
Net income: net loss was approximately $10.9 million
EPS: $0.23 per share
Result: reported results

Exact text from the filing

For the first quarter of 2024, net loss was approximately $10.9 million, or $0.23 per share

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

HYPERION DEFI, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-061954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.